



### Understanding the impact of cancer diagnosis and treatment on everyday life

# **12 MONTH CERVICAL CANCER CRF**

## FOR STAFF USE ONLY

#### **CRF Completion Instructions**

- Please complete as much of the CRF as possible
- Please refer to your copy of the 6 month CRF when completing this 12 month CRF: please complete any additional treatment details that were not captured at 6 months (for example, additional treatments, or end dates of those ongoing at 6 months)
- If you have any queries, please contact the HORIZONS Co-ordinating Centre, email address <u>HORIZONS@soton.ac.uk</u>
- Please tick boxes when appropriate
- When you have completed the CRF, please keep a copy for your own records and return a copy to us, by post, fax or email along with the completed return cover sheet

©2025. This work is openly licensed by <u>CC BY-NC-SA</u>

Participant's Study ID		]/[		/					
Participant's date of birth	d	d	m	m	У	У	У	У	

Has the participant had any genetic tests for inherited cancers? (please tick one box)

Yes (already recorded in previous CRF)	
Yes (but not recorded in previous CRF)	
No	
Unknown	

If you answered "Yes (but not recorded in previous CRF)" to the above question, please provide some information about the participant's other genetic test(s) by completing the table(s) below

Name of genetic test for cancer (1)	Result of genetic test
	Positive
	Negative
	Ambiguous/uncertain
	Awaiting result
	Unknown

Name of genetic test for cancer (2)	Result of genetic test
	Positive
	Negative
	Ambiguous/uncertain
	Awaiting result
	Unknown

HORIZONS 12 month Case Report Form; Cervical. Version 1.0, 24/08/2017, IRAS Project ID: 202342, REC reference number 16/NW/0425

Participant's	Study ID
---------------	----------



Has the participant developed any NEW co-morbidities (which were not recorded in the baseline or 6 month CRF)? (please tick all that apply in the tables below and overleaf)

Myocardial infarct	
Angina/coronary artery disease	
Congestive Heart Failure	
Cardiac Arrythmias	
Hypertension	
Venous Disease (PE/DVT)	
Peripheral Arterial Disease	
Restrictive Lung Disease or COPD (chronic bronchitis, emphysema, asthma etc.)	
Liver Disease (portal hypertension, chronic/acute hepatitis, cirrhosis etc.)	
Stomach Ulcers or Inflammatory Bowel Disease	
Acute or Chronic Pancreatitis	
End-stage Renal Disease (chronic renal insufficiency, dialysis etc.)	
Thyroid problems (hyperthyroidism, hypothyroidism etc.)	
Diabetes Mellitus Type 1	
Diabetes Mellitus Type 2	
Stroke/TIA	
Dementia	
Paralysis (paraplegia or hemiplegia)	
Neuromuscular Condition (multiple sclerosis, Parkinson's, myasthenia gravis, other chronic neuromuscular disorder)	
Clinical diagnosis of anxiety	

HORIZONS 12 month Case Report Form; Cervical. Version 1.0, 24/08/2017, IRAS Project ID: 202342, REC reference number 16/NW/0425

Participant's

Study ID		

Clinical diagnosis of depression	
Psychiatric Diagnosis (e.g. schizophrenia, bipolar disorder)	
Osteoarthritis	
Rheumatoid Arthritis	
Other Rheumatological Disease (systemic lupus, mixed connective tissue disorder, poly- myositis, rheumatic polymyositis, scleroderma etc.)	
HIV/AIDS	
Alcohol Abuse (or history of, must be accompanied by social, behavioural or medical com- plications)	
Drug/Substance Abuse (or history of, must be accompanied by social, behavioural or medical complications)	
Morbid Obesity	
Other (please give details)	
Other (please give details)	
Other (please give details)	

#### Is the participant pre or post menopause? (please tick one box)

Pre menopause	
Post menopause	
Unknown	

Participant's Study ID



What treatments has the participant received **since those captured at 6 months**, please tick ALL that apply and write details in the spaces provided. Please add end dates for any treatments which were ongoing at 6 months (table continued overleaf).

Treatment/ other pro- cedure	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treatment was not completed as planned, please give a reason why
Monoclonal Antibodies	Avastin (Bevacizumab)		/ / 20	/ / 20	
Surgery	Abdominal <b>total</b> hysterectomy		//20		
	Laparoscopic <b>total</b> hysterectomy		//20		
	Abdominal <b>radical</b> hysterectomy		//20		
	Laparoscopic radical hysterectomy		/_/20		
	Radical trachelectomy		//20		
	Lymphadenectomy		// 20		
	Other surgery (please describe)		//20		
Chemo- Radiation	CHEMOTHERAPY = Cisplatin		//20	//20	
(Continued	CHEMOTHERAPY = CarboTaxol (paclitaxel and carboplatin)		/ / 20	// 20	
overleaf)	CHEMOTHERAPY = Other (please describe)		//20	_/_/20	
	Chemotherapy number of cycles (	please en	ter on line)		

	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treatment was not completed as planned, please give a reason why		
	Combined external radio- therapy and brachytherapy		//20	//20			
	External radiotherapy		// 20	//20			
	Number of radiotherapy fi	ractions (ple	ase enter on line)				
	Dose for each radiotherapy	rfraction (pl	ease enter on line)				
	Intrauterine Image Guided- Brachytherapy (IGBT)		//20	// 20			
	Number of radiotherapy fractions (please enter on line)						
	Dose for each radiotherapy fraction (please enter on line)						
	Were interstitial needles used? (please tick one)	Yes	Nc	)			
	Intravaginal Image Guided- Brachytherapy (IGBT)		//20	//20			
	Number of radiotherapy fr	actions (ple	ase enter on line)				
	Dose for each radiotherapy	y fraction (p	lease enter on line)				
	Were interstitial needles Yes No   used? (please tick one) Yes No						
Additional	If any additional treatment		// 20	// 20			
Treatment	has been given please describe						

Participant's Study ID						
Has the participant had a <b>local</b> recurrence of their cervical cancer? (please tick one box)						
If the participant has had a local recurrence, on what date was the recurrence						
diagnosed?						
Since the participant's diagnosis of cervical cancer, has there been any evidence of distant metastatic disease? (please tick one box)						
Yes No Unknown						
If you have answered "yes" to the above question, on what date was the metastatic disease diagnosed:						
d d m m y y y						
Please provide details of the site(s) of distant metastatic disease:						
Is the participant taking part in a clinical trial? (please tick one box)       Yes     No     Unknown						
If you answered "yes" to the above question, please give the NAME of the clinical trial the participant is taking part in						
Name of clinical trial						

Participant's Study ID		/	1			
------------------------	--	---	---	--	--	--

Since the participant's diagnosis of cervical cancer, have they been diagnosed with another new primary cancer? (please tick one box)

If you answered "yes" to the above question, please provide some information about the participant's new cancer diagnosis by completing the table below

Type of cancer	
Date of diagnosis	//20
Treatment received	
Date treatment ended (if finished)	/ / 20

What type of follow-up care is the participant receiving? (please tick ONE box)

Routine/regular hospital clinic based follow-up (medical or nurse led,	
face-to-face or by telephone)	
Primary care based follow-up	
Patient initiated follow-up (also known as patient triggered follow-up (PTFU), open access follow-up, or supported self-managed follow-up)	
If the participant is receiving patient-initiated follow-up, on what date were they discharged to this?	

Participant's Study ID



Has the participant been referred to any of the following services and/or had a Holistic Needs Assessment? (please tick all that apply)

Participant has been referred to palliative care services	
Participant has been referred to psychological services If ticked, please provide route to referral (e.g. GP, Improving Access to Psychological Therapies)	
Participant has been referred to community services	
Participant has been referred for treatment related problems (e.g. urology, gastroenterology) If ticked, please provide more details below:	
Participant has had an HNA (holistic needs assessment)	

If the participant has died please give the date and cause of death:

Participant's date of death

d d	/	m	m	/	У	У	У	У

Cause of participant's death

Cause of death not known

1) a)	
1) b)	
1) c)	
2)	

Please add your name and signature and the date that you completed this CRF

Name	Signature	
Date CRF completed	d d / m m / y y y	

HORIZONS 12 month Case Report Form; Cervical. Version 1.0, 24/08/2017, IRAS Project ID: 202342, REC reference number 16/NW/0425